

Eric Shih Katsuyama
12 posts

@erickatsuyama97
🎓 | MD 🇧🇷 | FMABC 2021 🔬 | Teaching Assistant II PPCR 2024 @harvardchansph 📊 | Director of Specialties and Mentorat @metaacademy_ofc













👥Systematic meta-analysis of 10 RCTs (>22,000 pts - 51.2% w/T2DM) to determine the impact of SGLT2i in pts w/ recent or previous MI. 🗓️Mean age 62 yrs; median FU was 21 months. Main findings: 💥HF hospitalization rates were ⬇️in pts on SGLT2i compared with placebo (RR 0.77; 95% CI 0.69, 0.85; p<0.001). 💥These benefits of SGLT2i were consistent regardless of the timing of the last MI. 💥No statistically significant difference in all-cause mortality was observed between the groups (RR 0.88; 95% CI 0.78, 1.00; p=0.058). Read more on #CardiovascularDiabetology @BioMedCentral 👇 cardiab.biomedcentral.com/articles/10.11…




The countdown to the New Year has begun! 🚀 Show us a paper you presented or published this year—we love to see our #MetaMasters going to the moon! 🌕
